Alumis (ALMS) Stockholders Approve Merger with ACELYRIN (SLRN) May 13, 2025 01:00PM
Acelyrin (SLRN) Stockholders Approve Merger with Alumis (ALMS) May 13, 2025 01:00PM
Acelyrin (SLRN) Reiterates Benefits of Value-Maximizing Combination with Alumis (ALMS) May 1, 2025 01:31PM
Alumis (ALMS) and ACELYRIN (SLRN) to Merge Apr 21, 2025 06:36AM
Alumis (ALMS) and Acelyrin (SLRN) file joint proxt statement for merger Apr 4, 2025 04:36PM


Mar 13, 2025 07:01AM Acelyrin (SLRN) Adopts Limited-Duration Stockholder Rights Plan
Mar 4, 2025 09:05AM Alumis (ALMS) and ACELYRIN (SLRN) Reaffirm Strategic and Financial Rationale of Proposed Merger
Feb 21, 2025 07:21AM Acelyrin (SLRN) Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Feb 12, 2025 12:51PM SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Acelyrin, Inc. Buyout
Feb 6, 2025 04:16PM Alumis (ALMS) and ACELYRIN (SLRN) to Merge
Jan 7, 2025 08:30AM Acelyrin Inc (SLRN) PT Lowered to $3 at Citi
Jan 7, 2025 06:51AM Acelyrin Inc (SLRN) PT Lowered to $6 at H.C. Wainwright
Jan 7, 2025 01:45AM Piper Sandler Reiterates Overweight Rating on Acelyrin Inc (SLRN)
Jan 6, 2025 04:00PM Acelyrin (SLRN) Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease
Dec 11, 2024 07:24AM H.C. Wainwright Reiterates Neutral Rating on Acelyrin Inc (SLRN)
Dec 10, 2024 04:50PM After-hours movers: GM, Stitch Fix, Dave & Buster's, GME and more
Dec 10, 2024 04:31PM Acelyrin (SLRN) Phase 2b/3 trial of izokibep did not meet primary endpoint
Dec 10, 2024 04:25PM Acelyrin (SLRN) Halted, News Pending
Nov 14, 2024 01:17PM TD Cowen Reiterates Buy Rating on Acelyrin Inc (SLRN)
Nov 14, 2024 06:58AM Acelyrin Inc (SLRN) PT Raised to $8 at H.C. Wainwright
Nov 13, 2024 05:20PM Acelyrin, Inc. (SLRN) Tops Q3 EPS by 70c
Sep 25, 2024 07:19AM Piper Sandler Reiterates Overweight Rating on Acelyrin Inc (SLRN)
Sep 10, 2024 07:07AM Acelyrin (SLRN) Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented
Aug 19, 2024 08:20AM Acelyrin Inc (SLRN) PT Lowered to $6 at Morgan Stanley
Aug 14, 2024 11:02AM TD Cowen Reiterates Buy Rating on Acelyrin Inc (SLRN)
Aug 14, 2024 09:25AM Acelyrin Inc (SLRN) PT Lowered to $6 at Citi
Aug 14, 2024 08:15AM Acelyrin Inc (SLRN) PT Lowered to $20 at Piper Sandler
Aug 14, 2024 06:13AM H.C. Wainwright Downgrades Acelyrin Inc (SLRN) to Neutral
Aug 13, 2024 04:57PM After-hours movers: Alphabet, Flutter Entertainment, DraftKings
Aug 13, 2024 04:49PM Acelyrin, Inc. (SLRN) Tops Q2 EPS by 22c
Aug 13, 2024 04:00PM Acelyrin (SLRN) Reports Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa
Jul 8, 2024 06:13AM Wells Fargo Upgrades Acelyrin Inc (SLRN) to Overweight